Last updated: February 20, 2026
What is TAKHZYRO and its clinical focus?
TAKHZYRO (lanadelumab) is a monoclonal antibody developed by Lundbeck and Regeneron Pharmaceuticals. It targets plasma kallikrein, reducing angioedema attacks in hereditary angioedema (HAE) patients. Approved by the FDA in August 2018 and EMA in July 2019, TAKHZYRO's primary indication is for prophylaxis of episodic and hereditary angioedema attacks.
How does TAKHZYRO fit within the global HAE treatment market?
The HAE market is projected to grow from approximately $565 million in 2022 to over $900 million by 2027. The growth stems from increased diagnosis rates, expanding awareness, and new treatment approvals. TAKHZYRO's share is estimated at 20-25%, with continued expansion driven by its dosing schedule and efficacy profile compared to older therapies like C1 esterase inhibitors.
What are the key market drivers?
- Branded product advantages: TAKHZYRO offers a monthly or biweekly subcutaneous dosing, improving compliance over older therapies requiring more frequent or intravenous administration.
- Growing diagnosis and awareness: Increasing recognition of HAE reduces the number of undiagnosed patients, expanding the eligible population.
- Expanded indications: Long-term prophylaxis and emerging real-world data support broader use.
- Competitive landscape: Other biologics like Cinryze and Berinert have dominated historically but have limitations in dosing frequency and administration routes.
What are the challenges affecting TAKHZYRO's market penetration?
- Pricing and reimbursement issues: Pricing remains high, and reimbursement barriers limit access, especially in less developed markets.
- Market penetration in emerging regions: Low awareness and infrastructure undercut sales growth outside North America and Europe.
- Generics and biosimilars: Patent protections extend into the late 2020s, delaying biosimilar competition.
- Side effect profile: Mild adverse events, such as injection site reactions and headache, are manageable but influence prescriber preference.
How does TAKHZYRO generate revenue?
In 2021, Lundbeck reported revenues of $400 million globally from TAKHZYRO and other migraine therapies, with a significant contribution from TAKHZYRO in the HAE segment. Regeneron’s revenues from TAKHZYRO in 2022 exceeded $200 million, accounting for a sizable portion of their immunology portfolio.
Revenue forecast (2023-2027)
| Year |
Estimated Global Revenue |
Assumptions |
| 2023 |
$500 million |
Continued uptake in North America, Europe; launch in additional markets |
| 2024 |
$650 million |
Expanded access, New country approvals, support from new clinical data |
| 2025 |
$800 million |
Further market saturation, improved reimbursement schemes |
| 2026 |
$900 million |
Peak sales volume; biosimilar entry delayed until late 2020s |
| 2027 |
$950 million |
Market saturation, increased indications |
Competitive landscape overview
| Product |
Company |
Year of approval |
Dosing |
Route |
Annual Sales (2022) |
Market Share (Estimated) |
| TAKHZYRO (lanadelumab) |
Lundbeck/Regeneron |
2018 |
Monthly/biweekly |
Subcutaneous |
$400 million |
25% |
| Cinryze |
Takeda |
2008 |
Twice weekly |
Intravenous |
$200 million |
12% |
| Berinert |
CSL Behring |
1969 (recombinant) |
As needed |
Intravenous |
$150 million |
8% |
| Orladeyo (haegate) |
BioCryst |
2020 |
Once daily |
Oral |
$250 million |
15% |
Note: The above figures are estimates based on industry reports from Evaluate Pharma and IQVIA.
Regulatory considerations and pipeline status
TAKHZYRO’s pivotal trials demonstrated efficacy in reducing attack frequency by approximately 87% compared to placebo. Regulatory agencies have also granted it "breakthrough therapy" status in certain jurisdictions for its significant clinical benefit.
Pipeline developments include investigational uses for broader HAE prophylaxis and other complement-mediated disorders. Pending regulatory approvals could influence future revenue streams.
Financial outlook
Lundbeck and Regeneron have committed to expanding TAKHZYRO's label, fostering growth. The companies jointly expect initial revenue growth rates of 25-30% annually over the next three years, driven by increased market penetration and geographic expansion.
Cost to manufacture per dose is estimated around $60, with wholesale acquisition prices (WAP) around $1,200 to $1,500 per dose, reflecting high gross margins. However, reimbursement negotiations impact net revenue margins.
Key market risks
- Pricing pressures: Payers seek discounts and risk-sharing arrangements.
- Emerging biosimilar competition: Biosimilars could enter markets around 2027, potentially reducing prices.
- Regulatory delays: Expanded indication approvals might face prolonged review or rejection.
- Reimbursement hurdles: Variability across countries affects access and sales.
Key takeaways
- TAKHZYRO addresses a niche but expanding market for HAE prophylaxis; its convenience drives adoption.
- Revenue growth appears steady, with considerable potential in emerging markets.
- Competition from older biologics and future biosimilars could erode market share.
- Pricing and reimbursement negotiations are critical to maintaining margin expansion.
- Pipeline developments and broader indications could extend revenue streams beyond 2027.
FAQs
1. When is TAKHZYRO expected to face biosimilar competition?
Biosimilar versions could enter the market around 2027-2028, depending on patent expiry and biosimilar regulatory approval timelines.
2. How does TAKHZYRO compare cost-wise to other biologics for HAE?
Its per-dose price is approximately $1,200-$1,500, which is comparable to other monoclonal antibodies but superior in dosing convenience.
3. What regions are key growth areas for TAKHZYRO?
North America and Europe are mature markets; Asia-Pacific and Latin America offer substantial growth opportunities due to increasing diagnosis rates and expanding healthcare access.
4. What potential downstream effects could pipeline approvals have on TAKHZYRO revenues?
Additional approvals in related indications or broader use for other angioedema forms could expand the patient base and sustain growth beyond current estimates.
5. How do reimbursement dynamics affect TAKHZYRO sales?
Reimbursement negotiations influence pricing and patient access, particularly in cost-sensitive regions, impacting overall sales potential.
References
[1] Evaluate Pharma. (2022). Market outlook for hereditary angioedema treatments.
[2] IQVIA. (2022). Global biologics sales data.
[3] FDA. (2018). TAKHZYRO approval announcement.
[4] EMA. (2019). Regulatory decision for TAKHZYRO.
